

## APPENDIX I

<b>Proposed Counts' Claim Text</b>	<b>Exemplary Disclosure in the '625 Application<sup>9</sup></b>
<p>54. A vaccine which protects a pig against a porcine reproductive and respiratory syndrome (PRRS),</p>	<p><b>Page 1, Lines 14-16:</b> "The present invention concerns a vaccine which protects pigs from a disease caused by respiratory and reproductive viruses"</p>
	<p><b>Page 14, Line 24 to Page 16, Line 15:</b>            "In the present invention, a 'porcine respiratory and reproductive disease' refers to the diseases PRRS, PNP and EMCV described above, the disease caused by the Iowa strain of PRRSV, and closely-related variants of these diseases which have appeared and which will appear in the future. A vaccine 'protects a pig against a disease caused by a porcine respiratory and reproductive disease virus or infectious agent' if, after administration of the vaccine to an unaffected pig, lesions in the lung or symptoms of the disease do not appear or are not as severe as in infected, unprotected pigs, and if, after administration of the vaccine to an affected pig, lesions in the lung or symptoms of the disease are eliminated or are not as severe as in infected, unprotected pigs. . . ."</p>
<p>comprising an effective amount of a biologically-pure virus selected from the group consisting of ISU-51 (VR 2429), ISU-55 (VR 2430), ISU-3927 (VR 2431), and ISU-1894 (VR 2475),</p>	<p><b>Page 32, Line 6 to Page 33, Line 3:</b>            "The present invention further concerns a biologically pure sample of a virus or infectious agent causing a porcine reproductive and respiratory disease . . . In particular, the present biologically pure virus or infectiouir agent is the Iowa strain of porcine reproductive and respiratory syndrome, samples of which have been deposited under the terms of the Budapest Treaty at the American Type Culture Collection . . . under the accession numbers VR 2385, VR 2386,</p>

<sup>9</sup> Applicants provide the following exemplary support for the cited claims and expressly reserve the right to amend and/or supplement the support listed.

Proposed Counts' Claim Text	Exemplary Disclosure in the '625 Application <sup>9</sup>
<p>wherein said virus is attenuated;</p> <p>and a physiologically-acceptable carrier,</p> <p>wherein said virus is prepared by serial passage in a cell line selected from the group consisting of PSP-36, PSP-36-SAH, and MA-104.</p>	<p>VR 2428, VR 2429, VR 2430, VR 2431, and VR 2472 . . . .<sup>10</sup></p> <p><b>Page 27, Lines 1-6:</b> "Attenuated virus vaccines can be found in nature and may have naturally-occurring gene deletions, or alternatively, may be prepared by a variety of known methods, such as serial passage in cell cultures or tissue cultures. Viruses can also be attenuated by gene deletions or gene mutations."</p> <p><b>Page 132, Original Claim 9:</b> "A composition for protecting a pig from viral infection, comprising an amount of the vaccine of Claim 1 effective to raise an immunological response to a virus which causes a porcine reproductive and respiratory disease in an physiologically acceptable carrier."</p> <p><b>Page 40, Lines 10-21:</b> "Preferably, the present vaccine is prepared from a virus or infectious agent cultured in an appropriate cell line. The cell line is preferably PSP-36 or an equivalent cell line capable of being infected with the virus and cultured. An example of a cell line equivalent to PSP-36 is the cell line PSP-36-SAH . . . . Another equivalent cell line is MA-104 . . . ."</p>
<p>55. A vaccine which protects a pig against a porcine reproductive and respiratory syndrome (PRRS),</p>	<p><b>Page 1, Lines 14-16:</b> "The present invention concerns a vaccine which protects pigs from a disease caused by respiratory and reproductive viruses"</p> <p><b>Page 14, Line 24 to Page 16, Line 15:</b> "In the present invention, a 'porcine respiratory and reproductive disease' refers to the diseases PRRS, PNP and EMCV described above, the disease caused by the Iowa strain of PRRSV, and closely-related variants of these diseases which have appeared and which will appear in the future. A vaccine</p>

<sup>10</sup> Deposit numbers were added by Amendment in the '625 Application dated August 21, 1995.

Proposed Counts' Claim Text	Exemplary Disclosure in the '625 Application <sup>9</sup>
<p>comprising an effective amount of a biologically-pure virus selected from the group consisting of ISU-51 (VR 2429), ISU-55 (VR 2430), ISU-3927 (VR 2431), and ISU-1894 (VR 2475), or a virus exhibiting the identifying characteristics of a virus in said group,</p> <p>wherein said virus is attenuated;</p> <p>and a physiologically-acceptable carrier,</p>	<p>'protects a pig against a disease caused by a porcine respiratory and reproductive disease virus or infectious agent' if, after administration of the vaccine to an unaffected pig, lesions in the lung or symptoms of the disease do not appear or are not as severe as in infected, unprotected pigs, and if, after administration of the vaccine to an affected pig, lesions in the lung or symptoms of the disease are eliminated or are not as severe as in infected, unprotected pigs. . . ."</p> <p><b>Page 32, Line 6 to Page 33, Line 3:</b> "The present invention further concerns a biologically pure sample of a virus or infectious agent causing a porcine reproductive and respiratory disease . . . In particular, the present biologically pure virus or infectiour agent is the Iowa strain of porcine reproductive and respiratory syndrome, samples of which have been deposited under the terms of the Budapest Treaty at the American Type Culture Collection . . . under the accession numbers VR 2385, VR 2386, VR 2428, VR 2429, VR 2430, VR 2431, and VR 2472 . . . ."<sup>11</sup></p> <p><b>Page 27, Lines 1-6:</b> "Attenuated virus vaccines can be found in nature and may have naturally-occurring gene deletions, or alternatively, may be prepared by a variety of known methods, such as serial passage in cell cultures or tissue cultures. Viruses can also be attenuated by gene deletions or gene mutations."</p> <p><b>Page 132, Original Claim 9:</b> "A composition for protecting a pig from viral infection, comprising an amount of the vaccine of Claim 1 effective to raise an immunological response to a virus which causes a porcine reproductive and</p>

<sup>11</sup> Deposit numbers were added by Amendment in the '625 Application dated August 21, 1995.

Proposed Counts' Claim Text	Exemplary Disclosure in the '625 Application <sup>9</sup>
<p>wherein said virus is prepared by serial passage in a cell line selected from the group consisting of PSP-36, PSP-36-SAH, and MA-104.</p>	<p>respiratory disease in an physiologically acceptable carrier."</p> <p><b>Page 40, Lines 10-21:</b> "Preferably, the present vaccine is prepared from a virus or infectious agent cultured in an appropriate cell line. The cell line is preferably PSP-36 or an equivalent cell line capable of being infected with the virus and cultured. An example of a cell line equivalent to PSP-36 is the cell line PSP-36-SAH . . . Another equivalent cell line is MA-104 . . . ."</p>
<p>56. (New) A vaccine which protects a pig against a porcine reproductive and respiratory syndrome (PRRS),</p>	<p><b>Page 1, Lines 14-16:</b> "The present invention concerns a vaccine which protects pigs from a disease caused by respiratory and reproductive viruses"</p> <p><b>Page 14, Line 24 to Page 16, Line 15:</b> "In the present invention, a 'porcine respiratory and reproductive disease' refers to the diseases PRRS, PNP and EMCV described above, the disease caused by the Iowa strain of PRRSV, and closely-related variants of these diseases which have appeared and which will appear in the future. A vaccine 'protects a pig against a disease caused by a porcine respiratory and reproductive disease virus or infectious agent' if, after administration of the vaccine to an unaffected pig, lesions in the lung or symptoms of the disease do not appear or are not as severe as in infected, unprotected pigs, and if, after administration of the vaccine to an affected pig, lesions in the lung or symptoms of the disease are eliminated or are not as severe as in infected, unprotected pigs. . . ."</p>
<p>comprising an inactivated or attenuated virus wherein prior to inactivation or attenuation, said virus is selected from the group consisting of ISU-51 (VR 2429), ISU-55 (VR 2430), ISU-3927 (VR 2431), and ISU-1894 (VR 2475),</p>	<p><b>Page 32, Line 6 to Page 33, Line 3:</b> "The present invention further concerns a biologically pure sample of a virus or infectious agent causing a porcine reproductive and respiratory disease . . . In particular, the present biologically pure virus or infectiour agent is the Iowa strain</p>

Proposed Counts' Claim Text	Exemplary Disclosure in the '625 Application <sup>9</sup>
and a physiologically-acceptable carrier,	<p>of porcine reproductive and respiratory syndrome, samples of which have been deposited under the terms of the Budapest Treaty at the American Type Culture Collection . . . under the accession numbers VR 2385, VR 2386, VR 2428, VR 2429, VR 2430, VR 2431, and VR 2472 . . . ."<sup>12</sup></p> <p><b>Page 132, Original Claim 9:</b> "A composition for protecting a pig from viral infection, comprising an amount of the vaccine of Claim 1 effective to raise an immunological response to a virus which causes a porcine reproductive and respiratory disease in an physiologically acceptable carrier."</p>
wherein said inactivated or attenuated virus	<p><b>Page 27, Lines 1-6:</b> "Attenuated virus vaccines can be found in nature and may have naturally-occurring gene deletions, or alternatively, may be prepared by a variety of known methods, such as serial passage in cell cultures or tissue cultures. Viruses can also be attenuated by gene deletions or gene mutations."</p>
is prepared by serial passage in a cell line selected from the group consisting of PSP-36, PSP-36-SAH, and MA-104.	<p><b>Page 40, Lines 10-21:</b> "Preferably, the present vaccine is prepared from a virus or infectious agent cultured in an appropriate cell line. The cell line is preferably PSP-36 or an equivalent cell line capable of being infected with the virus and cultured. An example of a cell line equivalent to PSP-36 is the cell line PSP-36-SAH . . . . Another equivalent cell line is MA-104 . . . ."</p>

<sup>12</sup> Deposit numbers were added by Amendment in the '625 Application dated August 21, 1995.